Search research articles
Contact Us
Filters
Showing results (21-30 of 41) with videos related to
Page
of 5
Sort By:
The Annals of Thoracic Surgery
|
May 1, 1996
Multimodality therapy in stage III non-small cell lung cancer
M J Edelman, D R Gandara, M Roach, et al.
Oncology (Williston Park, N.Y.)
|
August 29, 2000
Gemcitabine/carboplatin combination regimens: importance of dose schedule
D R Gandara, D H Lau, P N Lara, et al.
Investigational New Drugs
|
December 16, 1998
Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer
M J Edelman, F J Meyers, T Grennan, et al.
Oncology (Williston Park, N.Y.)
|
April 17, 2001
Gemcitabine in combination with new platinum compounds: an update
D R Gandara, M J Edelman, P N Lara, et al.
Urology
|
February 1, 1996
The potential for reintroduction of tumor cells during intraoperative blood salvage: reduction of risk with use of the RC-400 leukocyte depletion filter
M J Edelman, P Potter, K G Mahaffey, et al.
Seminars in Oncology
|
April 14, 1999
Gemcitabine and carboplatin in combination: an update of phase I and phase II studies in non-small cell lung cancer
C J Langer, D R Gandara, P Calvert, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1997
Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study
D R Gandara, M J Edelman, J J Crowley, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
June 18, 1998
Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration
D R Gandara, F Roila, D Warr, et al.
Cancer
|
July 10, 2001
Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel
M J Edelman, D R Gandara, D H Lau, et al.
Urology
|
March 29, 2000
Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutation
M J Edelman, F J Meyers, T R Miller, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 41) with videos related to
Sort By:
Page
of 5
The Annals of Thoracic Surgery
|
May 1, 1996
Multimodality therapy in stage III non-small cell lung cancer
M J Edelman, D R Gandara, M Roach, et al.
Oncology (Williston Park, N.Y.)
|
August 29, 2000
Gemcitabine/carboplatin combination regimens: importance of dose schedule
D R Gandara, D H Lau, P N Lara, et al.
Investigational New Drugs
|
December 16, 1998
Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer
M J Edelman, F J Meyers, T Grennan, et al.
Oncology (Williston Park, N.Y.)
|
April 17, 2001
Gemcitabine in combination with new platinum compounds: an update
D R Gandara, M J Edelman, P N Lara, et al.
Urology
|
February 1, 1996
The potential for reintroduction of tumor cells during intraoperative blood salvage: reduction of risk with use of the RC-400 leukocyte depletion filter
M J Edelman, P Potter, K G Mahaffey, et al.
Seminars in Oncology
|
April 14, 1999
Gemcitabine and carboplatin in combination: an update of phase I and phase II studies in non-small cell lung cancer
C J Langer, D R Gandara, P Calvert, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1997
Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study
D R Gandara, M J Edelman, J J Crowley, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
June 18, 1998
Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration
D R Gandara, F Roila, D Warr, et al.
Cancer
|
July 10, 2001
Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel
M J Edelman, D R Gandara, D H Lau, et al.
Urology
|
March 29, 2000
Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutation
M J Edelman, F J Meyers, T R Miller, et al.
Page
of 5